Extracellular vesicle-based drug delivery systems for cancer treatment.
Walker S, Busatto S, Pham A, Tian M, Suh A, Carson K, Quintero A, Lafrence M, Malik H, Santana MX, Wolfram J. · 2019
Read Extracellular vesicle-based drug delivery systems for cancer treatment. by Walker S, Busatto S, Pham A, Tian M, Suh A, Carson K, Quintero A, Lafrence M, Malik H, Santana MX, Wolfram J. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6857056.txt.
Introduction
Walker and co-authors review vesicle-based drug delivery in Theranostics. Cells naturally shed tiny bubbles called extracellular vesicles. These carry proteins, RNAs, and fats between cells as messages. Their surfaces bear molecules that steer them toward certain tissues. Drug makers hope to borrow that courier system to treat cancer.
The review covers how vesicles are collected and loaded with drugs. It also covers changes made to help them circulate longer and hit tumours more precisely. In mouse studies, drug-loaded vesicles shrank tumours more than the same drugs given free. Some even worked better on drug-resistant cells. The authors weigh remaining hurdles in dosing, manufacture, and safety.
Catalog record
| CREATOR | Walker S, Busatto S, Pham A, Tian M, Suh A, Carson K, Quintero A, Lafrence M, Malik H, Santana MX, Wolfram J. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 78 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Extracellular vesicle-based drug delivery systems for cancer treatment By Sierra Walker, Sara Busatto, Anthony Pham, Ming Tian, Annie Suh, Kelsey Carson, Astrid Quintero, Maria Lafrence, Hanna Malik, Moises X. Santana, Joy Wolfram Published in: Theranostics DOI: 10.7150/thno.37097 ABSTRACT Extracellular vesicles (EVs) are naturally occurring cell-secreted nanoparticles that play important roles in many physiological and pathological processes. EVs enable intercellular communication by serving as delivery vehicles for a wide range of endogenous cargo molecules, such as RNAs, proteins, carbohydrates, and lipids. EVs have also been found to display tissue tropism mediated by surface molecules, such as integrins and glycans, making them promising for drug delivery applications. Various methods can be used to load therapeutic agents into EVs, and additional modification strategies have been employed to prolong circulation and improve targeting. This review gives an overview of EV-based drug delivery strategies in cancer therapy. 1. INTRODUCTION The term extracellular vesicle (EV) refers to a wide variety of biological nanoparticles that engage in cell-to-cell communication (paracrine and autocrine) within micro and macroenvironments 1. These secreted membrane-contained nanoparticles are formed from the cell membrane (microvesicles, typically 50-1,000 nm), multivesicular bodies (exosomes, typically 40-100 nm), or apoptotic structures (apoptotic bodies, typically 800-5,000 nm) 2-4. The Minimal Information for Studies of Extracellular Vesicles guidelines proposed by the International Society for Extracellular Vesicles (ISEV) should be followed in regard to EV nomenclature. The general term EV should be used unless direct evidence of biogenesis exists (e.g. microscopy). In cases where proof of basic EV characteristics, such as size, lipid bilayer, and protein markers are lacking, the term extracellular particle should be used 2. Many cell types have been found to secrete EVs, and this is likely a universal feature of all cells due to the dynamic nature of the cell membrane. Namely, from a pure physicochemical perspective, the absence of any form of membrane blebbing during the life span of a cell is improbable. However, in most cell types EV formation is linked to a biological function and includes some type of active sorting. The biological activity of EVs depends on the surface composition and cargo, which typically consists of RNAs, proteins, lipids, carbohydrates, and in certain cases DNA 3, 5. The composition of EVs can be representative of the biological status of a cell, and usually differs from the cytoplasmic content. EVs are involved in many physiological and pathological processes, such as cancer pathogenesis. The complex process of tumor growth encompasses communication between multiple cell types, including cancer cells, endothelial cells, fibroblasts, and immune cells 6-8. EVs have been found to transfer biomolecules, such as proteins and nucleic acids, which promote tumor growth and progression within the primary organ or secondary sites of metastasis 9, 10. Despite being involved in tumor progression, EVs from both healthy and diseased cells can be exploited for therapeutic purposes as targets, immunomodulators, and drug delivery vehicles 1, 10-12. Due to the broad scope of possible EV applications, this review focuses on the use and efficacy of EVs derived from eukaryotic cells as drug delivery systems for cancer treatment. Other approaches involving EV-like particles used as anti-cancer vaccines 13 or antiviral therapeutics 13 are not reviewed. Despite substantial contributions to cancer treatment, chemotherapy is prone to rapid clearance, poor bioavailability, low intratumoral delivery, unspecific cytotoxicity, and consequent systemic side effects, frequently followed by the onset of tumor resistance 14. To overcome these challenges, a plethora of synthetic nanodelivery vehicles have been developed, some of which are clinically approved 15, 16. In addition to reducing renal clearance and improving site-specific delivery through shape (e.g. discoidal particles to enhance interactions with tumor vasculature) 17 and/or ligand-based 18, 19 tumor tropism, artificial drug carriers enable simultaneous delivery of multiple therapeutic agents 20, 21, protection from enzymatic degradation 22, 23, immunoevasion 24, 25, sequential multistage release 26, 27, stimuli-responsive activation 17, 28, and theranostic capabilities 29. Nevertheless, the majority of these features are not yet in clinical use, partially due to complex and costly manufacturing required to achieve multi-functionality. The largest category of clinically approved nanoparticles is liposomes, which consist of a simple lipid bilayer surrounding an aqueous compartment 30. Liposomes are versatile drug delivery vehicles, as both the lipid membrane and interior space can be utilized for loading of hydrophobic and hydrophilic drugs, respectively. Similarly, EVs can be utilized as drug carriers for both water-soluble and non-water-soluble therapeutic agents. Additionally, EVs represent promising alternatives to synthetic nanoparticles, as they can exhibit intrinsic organotropic and tumor-targeting abilities 31. For instance, EV-associated integrins (ITGs) have been shown to direct tissue-specific colonization by interacting with target cells. Such ITGs bind to receptors found in the extracellular matrix such as laminin or other compatible ITGs 32. For example, ITGα6, ITGβ4, and ITGβ1 are present in lung-tropic EVs, while ITGβ5 has been found in liver-tropic EVs 32. The ability to obtain EV populations that display favorable properties could enable exploitation of complex multifaceted drug delivery mechanisms while circumventing complicated manufacturing processes. However, one of the major limitations of EV-based drug delivery has been the lack of efficient isolation methods. Although a variety of options exist for concentrating EVs from biological sources, including centrifugation (high speed, differential, and density-gradient) (Figure 1A), size exclusion chromatography (SEC) (Figure 1B), membrane affinity columns, filtration (Figure 1C), and precipitation (Figure 1D), these methods display several limitations. In particular, conventional EV isolation techniques have limited yields, low purity, and inadequate batch-to-batch consistency 2. For example, precipitation-based methods have been found to co-precipitate both larger and smaller contaminants. Although this method is capable of concentrating EVs from biological samples with low volumes, a recent study demonstrated that 9-15% of plasma proteins and 21-99% of non-EV associated microRNAs (miRNA) co-precipitate, resulting in low purity 33. Newer methods, such as tangential flow filtration represent promising alternatives for improving time-efficiency, reproducibility, and quality 34, thereby opening up new opportunities for clinical translation. Ultracentrifugation, SEC, and filtration techniques depend primarily on particle size for separation, thus nanoparticles with overlapping ranges, such as microvesicles and exosomes, are indistinguishable by these isolation methods 35. Therefore, it is also critical to thoroughly characterize EVs according to minimal criteria reported by ISEV 2. In particular, morphology, concentration, presence of EV-enriched markers, and lack of contaminant markers should be evaluated, in addition to size distribution 2. 2. PHARMACOKINETICS Nano-sized particles are recognized by the immune system through various processes, many of which originate from defense mechanisms against bacteria and viruses, which have similar dimensions. Immunorecognition often leads to nanoparticle accumulation in the liver due to size-dependent infiltration through vascular fenestrations 36 and uptake by resident macrophages 24, which is in contrast to the rapid renal clearance seen with chemotherapy. Both synthetic 37 and biological 38 nanoparticles are prone to rapid hepatic clearance due to immunological recognition, which limits intratumoral accumulation. Although most studies have reported that EVs are cleared from circulation in a few minutes 39, 40, pharmacokinetics are likely highly dependent on EV source, subpopulation, isolation procedure, labeling method, and administration route. In fact, EV isolation and modification procedures may lead to membrane damage, which could trigger the immune system. Furthermore, it is possible that molecules used for EV tracking cause immunorecognition. As can be expected, studies have also demonstrated that the use of